Latest Content

The top 5 OncLive TV videos of the week cover insights in breast cancer, uveal melanoma, colorectal cancer, multiple myeloma, and sarcoma.

The FDA approved Orca-T, issued a CRL to a NET imaging agent, and more.

Divesiran lowered phlebotomy needs, raised ferritin, and improved MPN-10 symptom scores in phlebotomy-dependent polycythemia vera.

A Dana-Farber study identified an RNA surveillance defect that fuels melanoma through endogenous retroviral RNA.

Belantamab mafodotin–based therapy improved sustained MRD negativity rates in relapsed/refractory multiple myeloma.

Updated COMMANDS data showed durable RBC transfusion independence and a positive overall survival trend with luspatercept in lower-risk MDS.

Robert A. Winn, MD, discussed his path to becoming a physician, scientist, and leader at Fox Chase Cancer Center.

Updated analyses from a phase 2a study suggest durable survival with namodenosen in a subset of heavily pretreated patients with advanced PDAC.

Need a refresh on the current regulatory landscape for GI oncology? We've got you covered. Here's everything that moved the needle across GI malignancies this month.

Panelists discuss how nodal burden, NGS turnaround time, and regional resource heterogeneity shape treatment sequencing in EGFR-mutated NSCLC in Latin America.

Zanubrutinib plus R-BAP produced responses in both younger and older patients with previously untreated mantle cell lymphoma.

Breast oncologists weigh the future role of radiographic progression vs liquid biopsy in the timing of therapeutic shifts in metastatic breast cancer.

Sylvester cancer researchers became wildland firefighters themselves to study, from the inside, cancer risks tied to the job.

The FDA has granted breakthrough device designation to Merlin CP-GEP, a clinicopathologic gene expression profile test for early-stage cutaneous melanoma.

Brian Myre, MD, discusses phase 1 data with the novel in situ SYNC-T Therapy SV-102 and the ongoing phase 2 LEGION-100 study in prostate cancer.

Drs Nunnery and Iyengar discuss FAQs about the metabolic effects of breast cancer therapy and the expanding role of GLP-1 receptor agonists in oncology.

The FDA approved Orca-T for use in matched donor HSCT with a myeloablative preparative regimen in hematological malignancies.

Experts convened to discuss ADC sequencing strategies, biomarker testing infrastructure, and emerging data across cervical, ovarian, and endometrial cancers.

Frontline zanubrutinib plus rituximab yielded significant efficacy improvements over SOC chemoimmunotherapy for mantle cell lymphoma.

Mayo Clinic shows thymus preps CD8 T cells and uncovers molecular structures of PKCβ, a protein linked to cancer, refining immunotherapy.

In a recent OncLive Peer Exchange, expert investigators discussed the utility of ctDNA and MRD testing in solid tumors.

Both annamycin-containing arms produced numerically higher CR and CRc rates vs cytarabine alone in relapsed/refractory AML.

Epcoritamab plus lenalidomide reduced the risk of disease progression or death vs R-GemOx in relapsed/refractory DLBCL in the EPCORE DLBCL-4 trial.

The FDA has issued a CRL to LNTH-2501 for the localization of SSTR-positive NETs.

Romiplostim N01 supported platelet engraftment after unrelated umbilical cord blood transplantation with no serious TRAEs in hematologic malignancies.

The European Union approved trastuzumab deruxtecan for previously treated, HER2-postive metastatic solid tumors.

A Dana-Farber team developed an artificial intelligence method that designs proteins to recognize and hold specific drug molecules.

SB27, a proposed pembrolizumab biosimilar, met primary end points in both a phase 1 pharmacokinetic and a phase 3 efficacy study.

Milana V. Dolezal, MD, MSci, notes how the CLEOPATRA trial paved the way for further breast cancer research and highlighted data from DESTINY-Breast09.

The top 5 OncLive TV videos of the week cover insights in breast cancer, lymphoma, melanoma, prostate cancer, and ovarian cancer.

The FDA has approved new sacituzumab govitecan indications in TNBC, cleared palbociclib combination maintenance treatment in HER2-positive breast cancer, and more.

The enzalutamide bioequivalent received tentative FDA approval, pending patent expiry on branded Xtandi before final marketing authorization.

IV ST-001 nanoFenretinide produced a 28% response rate in heavily pretreated cutaneous T-cell lymphoma in a first-in-human phase 1a trial.

Real-world treatment with pegylated interferon alfa-2a tolerable, and treatment-related AEs were manageable in patients with cutaneous T-cell lymphoma.

The FDA approved a prefilled pen for the administration of ropeginterferon alfa-2b-njft in adult patients with polycythemia vera.

Translational profiling tied CCR4 loss, IL enrichment, and BCL-2 upregulation to mogamulizumab resistance; venetoclax may be a combination partner.

In a phase 1 trial, duvelisib plus nivolumab produced a 26% overall response rate in relapsed/refractory cutaneous T-cell lymphoma but was limited by immune-mediated toxicities.

Real-world mogamulizumab reduced skin symptoms and improved health-related quality of life in patients with mycosis fungoides and Sézary syndrome.

CHMP recommends pirtobrutinib for CLL across all treatment lines after phase 3 trials showed strong efficacy and a favorable safety profile.

CHMP backs teclistamab plus daratumumab for earlier use in relapsed/refractory multiple myeloma following strong MajesTEC-3 results.

Dibotatug was deemed tolerable and produced robust responses across subgroups of patients with relapsed/refractory cytotoxic T/NK cell lymphomas.

BI-1808 as a single agent and in combination with pembrolizumab elicited responses and was generally well tolerated in patients with CTCL.

The final analysis of the Italian FIL-MOGA study showed an objective response lasting at least 4 months in 47% of patients and identified the measure as a surrogate for survival outcomes.